About this trial
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common.Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist with skeletal muscle relaxant, sedative and anxiolytic properties.we carried out an open-label clinical trial in order to evaluate the efficacy and safety of combined treatment with tizanidine and pregabalin for pain in FM.
Eligibility criteria
Qualifiers
1.Aged 18-65 years. 2.Fulfill the 2016 updated American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia.
Disqualifiers
1.Presence of a painful condition, including inflammatory rheumatic disease, more than 50% as severe as but distinct from fibromyalgia.
Trial design
Treatments tested in this trial
- Pregabalin
- Pregabalin with tizanidine
Treatment groups
Sponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
People's Hospital of Xinjiang Uygur Autonomous Region
Collaborator
Sichuan Provincial People's Hospital
Collaborator